Phase II Study of Defactinib (VS6063) in Patients With Tumors With NF2 Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U.
Saved in:
| Title: | Phase II Study of Defactinib (VS6063) in Patients With Tumors With NF2 Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U. |
|---|---|
| Authors: | Zauderer MG; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY and Westchester Medical Center and New York Medical College, Valhalla, NY., Jegede O; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., Jackman DM; Dana Farber Cancer Institute, Boston, MA., Zwiebel JA; Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Gray RJ; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., Wang V; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., McShane LM; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Rubinstein LV; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Patton DR; Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD., Williams PM; Frederick National Laboratory for Cancer Research, Frederick, MD., Hamilton SR; City of Hope National Medical Center, Duarte, CA., Takebe N; Developmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Huang R; Brigham and Women's Hospital, Boston, MA., Carrillo JA; University of California, Irvine, CA., Brenner AJ; University of Texas Health Sciences Center, San Antonio, TX., Tricoli JV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Conley BA; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Arteaga CL; UT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX., Harris LN; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., O'Dwyer PJ; University of Pennsylvania, Philadelphia, PA., Chen AP; Developmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Flaherty KT; Massachusetts General Hospital Cancer Center, Boston, MA. |
| Source: | JCO precision oncology [JCO Precis Oncol] 2024 Dec; Vol. 8, pp. e2400327. Date of Electronic Publication: 2024 Dec 18. |
| Publication Type: | Journal Article; Clinical Trial, Phase II; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
